Absence of epidermal growth factor receptor mutations in cervical cancer

H. Arias-Pulido, N. Joste, A. Chavez, C. Y. Muller, D. Dai, Harriet O. Smith, C. F. Verschraegen

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) is overexpressed in the majority of cervical cancers (CCs). Somatic mutations of EGFR have been associated with clinical response to tyrosine kinase inhibitors (TKIs) in lung cancer patients. This study was designed to establish the frequency of EGFR point mutations in patients diagnosed with high-grade squamous intraepithelial lesions (HSIL) and CC. Nine cell lines derived from CC were screened for EGFR mutations in exons 18 through 21. Eighty-nine patient samples derived from invasive CC (n = 80) and HSIL (n = 9) were analyzed for the presence of EGFR mutations in exons 19 and 21. We found no mutations affecting the EGFR kinase domain in exons 18 through 21 in all cell lines tested, and no EGFR mutations were detected in exons 19 and 21 in all 89 human neoplastic samples analyzed. These data indicate that mutations in the EGFR kinase domain are very rare in CC and HSIL. Our results suggest, therefore, that treatment of CC patients with TKIs may not have the same efficacy as seen in patients with lung cancer, and that targeting the EGFR with other inhibitors may be more appropriate.

Original languageEnglish (US)
Pages (from-to)749-754
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume18
Issue number4
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Uterine Cervical Neoplasms
Mutation
Exons
Protein-Tyrosine Kinases
Lung Neoplasms
Cell Line
Point Mutation

Keywords

  • Cervical cancer
  • EGFR
  • Mutation analysis
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

Arias-Pulido, H., Joste, N., Chavez, A., Muller, C. Y., Dai, D., Smith, H. O., & Verschraegen, C. F. (2008). Absence of epidermal growth factor receptor mutations in cervical cancer. International Journal of Gynecological Cancer, 18(4), 749-754. https://doi.org/10.1111/j.1525-1438.2007.01111.x

Absence of epidermal growth factor receptor mutations in cervical cancer. / Arias-Pulido, H.; Joste, N.; Chavez, A.; Muller, C. Y.; Dai, D.; Smith, Harriet O.; Verschraegen, C. F.

In: International Journal of Gynecological Cancer, Vol. 18, No. 4, 07.2008, p. 749-754.

Research output: Contribution to journalArticle

Arias-Pulido, H, Joste, N, Chavez, A, Muller, CY, Dai, D, Smith, HO & Verschraegen, CF 2008, 'Absence of epidermal growth factor receptor mutations in cervical cancer', International Journal of Gynecological Cancer, vol. 18, no. 4, pp. 749-754. https://doi.org/10.1111/j.1525-1438.2007.01111.x
Arias-Pulido, H. ; Joste, N. ; Chavez, A. ; Muller, C. Y. ; Dai, D. ; Smith, Harriet O. ; Verschraegen, C. F. / Absence of epidermal growth factor receptor mutations in cervical cancer. In: International Journal of Gynecological Cancer. 2008 ; Vol. 18, No. 4. pp. 749-754.
@article{028c5535cd554496bcd8c955e0ae16c7,
title = "Absence of epidermal growth factor receptor mutations in cervical cancer",
abstract = "Epidermal growth factor receptor (EGFR) is overexpressed in the majority of cervical cancers (CCs). Somatic mutations of EGFR have been associated with clinical response to tyrosine kinase inhibitors (TKIs) in lung cancer patients. This study was designed to establish the frequency of EGFR point mutations in patients diagnosed with high-grade squamous intraepithelial lesions (HSIL) and CC. Nine cell lines derived from CC were screened for EGFR mutations in exons 18 through 21. Eighty-nine patient samples derived from invasive CC (n = 80) and HSIL (n = 9) were analyzed for the presence of EGFR mutations in exons 19 and 21. We found no mutations affecting the EGFR kinase domain in exons 18 through 21 in all cell lines tested, and no EGFR mutations were detected in exons 19 and 21 in all 89 human neoplastic samples analyzed. These data indicate that mutations in the EGFR kinase domain are very rare in CC and HSIL. Our results suggest, therefore, that treatment of CC patients with TKIs may not have the same efficacy as seen in patients with lung cancer, and that targeting the EGFR with other inhibitors may be more appropriate.",
keywords = "Cervical cancer, EGFR, Mutation analysis, Tyrosine kinase inhibitors",
author = "H. Arias-Pulido and N. Joste and A. Chavez and Muller, {C. Y.} and D. Dai and Smith, {Harriet O.} and Verschraegen, {C. F.}",
year = "2008",
month = "7",
doi = "10.1111/j.1525-1438.2007.01111.x",
language = "English (US)",
volume = "18",
pages = "749--754",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Absence of epidermal growth factor receptor mutations in cervical cancer

AU - Arias-Pulido, H.

AU - Joste, N.

AU - Chavez, A.

AU - Muller, C. Y.

AU - Dai, D.

AU - Smith, Harriet O.

AU - Verschraegen, C. F.

PY - 2008/7

Y1 - 2008/7

N2 - Epidermal growth factor receptor (EGFR) is overexpressed in the majority of cervical cancers (CCs). Somatic mutations of EGFR have been associated with clinical response to tyrosine kinase inhibitors (TKIs) in lung cancer patients. This study was designed to establish the frequency of EGFR point mutations in patients diagnosed with high-grade squamous intraepithelial lesions (HSIL) and CC. Nine cell lines derived from CC were screened for EGFR mutations in exons 18 through 21. Eighty-nine patient samples derived from invasive CC (n = 80) and HSIL (n = 9) were analyzed for the presence of EGFR mutations in exons 19 and 21. We found no mutations affecting the EGFR kinase domain in exons 18 through 21 in all cell lines tested, and no EGFR mutations were detected in exons 19 and 21 in all 89 human neoplastic samples analyzed. These data indicate that mutations in the EGFR kinase domain are very rare in CC and HSIL. Our results suggest, therefore, that treatment of CC patients with TKIs may not have the same efficacy as seen in patients with lung cancer, and that targeting the EGFR with other inhibitors may be more appropriate.

AB - Epidermal growth factor receptor (EGFR) is overexpressed in the majority of cervical cancers (CCs). Somatic mutations of EGFR have been associated with clinical response to tyrosine kinase inhibitors (TKIs) in lung cancer patients. This study was designed to establish the frequency of EGFR point mutations in patients diagnosed with high-grade squamous intraepithelial lesions (HSIL) and CC. Nine cell lines derived from CC were screened for EGFR mutations in exons 18 through 21. Eighty-nine patient samples derived from invasive CC (n = 80) and HSIL (n = 9) were analyzed for the presence of EGFR mutations in exons 19 and 21. We found no mutations affecting the EGFR kinase domain in exons 18 through 21 in all cell lines tested, and no EGFR mutations were detected in exons 19 and 21 in all 89 human neoplastic samples analyzed. These data indicate that mutations in the EGFR kinase domain are very rare in CC and HSIL. Our results suggest, therefore, that treatment of CC patients with TKIs may not have the same efficacy as seen in patients with lung cancer, and that targeting the EGFR with other inhibitors may be more appropriate.

KW - Cervical cancer

KW - EGFR

KW - Mutation analysis

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=47649119001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649119001&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2007.01111.x

DO - 10.1111/j.1525-1438.2007.01111.x

M3 - Article

C2 - 17949425

AN - SCOPUS:47649119001

VL - 18

SP - 749

EP - 754

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -